Biomea Fusion develops covalent small molecules that specifically target aggressive cancer types by inhibiting key mechanisms of disease progression. Their in-house R&D has produced multiple drug candidates currently in preclinical and clinical development, aimed at curing serious and life-threatening cancers.
Funding
$150M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers exhibit aggressive growth and resistance to conventional therapies due to dysregulation of key signaling pathways. Selectively targeting the underlying mechanisms driving disease progression remains a challenge in oncology drug development.
Solution
Biomea Fusion develops covalent small molecule inhibitors designed to selectively target and disable specific proteins involved in cancer progression. Their in-house R&D platform focuses on creating highly selective, targeted medicines that address key mechanisms of disease. These molecules are designed to covalently bind to their targets, leading to sustained inhibition and potentially improved efficacy. Biomea's approach aims to create therapies that can effectively treat serious and life-threatening cancers by intervening in fundamental disease processes.
Target Audience
The primary target audience includes patients with aggressive cancer types and the medical professionals who treat them, as well as pharmaceutical companies seeking novel oncology therapeutics.
Features
- Covalent small molecule drug design for irreversible target binding
- Focus on inhibiting key signaling pathways involved in cancer progression
- In-house R&D engine for target selection, molecule design, and preclinical/clinical studies
- Pipeline of drug candidates in preclinical and clinical development
- Development of highly selective and targeted medicines